Gates scholar co-author in major hypoglycaemia study

  • October 11, 2011
Gates scholar co-author in major hypoglycaemia study

Marina Minic plays important role in findings published in Science journal.

Gates scholar Marina Minic has played a key role in research which has identified the cause of a rare, life-threatening form of hypoglycaemia. 

The findings, published in the journal Science, have the potential to lead to pharmaceutical treatments for the disorder.

Hypoglycaemia, usually characterised by too much insulin which results in too little sugar in the bloodstream, is fairly common, often affecting diabetic patients or individuals with disorders that cause insulin overproduction.  Symptoms can include seizures and unconsciousness.

However, in an estimated 1 in 100,000 births a genetic defect causes a severe, life-threatening form of hypoglycaemia without detectable insulin in the bloodstream.  For this rare condition, the mainstay of treatment has been implantation of a surgical feeding tube through the front of the stomach to allow feeding during sleep.  This prevents patients’ blood glucose from dropping dangerously low overnight when monitoring is difficult and when symptoms often pass unnoticed.

Dr Robert Semple, Wellcome Trust Clinician Scientist at the Institute of Metabolic Science at the University of Cambridge, said:  “Fear of low blood sugar has dominated the lives of these patients and their families, and for many years the lack of an obvious cause has added to their anxiety.  Offering families an explanation for a rare disease is usually of great value to them in its own right, but in this case it is particularly exciting that our findings open the door for a new and specific treatment in the future.”

Scientists at the Institute of Metabolic Science and the Wellcome Trust Sanger Institute, working with clinical specialists in Cambridge, London and Paris, studied three children who suffered from this unusual form of hypoglycaemia.  By examining the children’s genetic code, they were able to identify the rare genetic alteration responsible for the disorder.  In all three children, but none of their parents, a single change in the AKT2 gene was identified.

AKT2 plays a critical role in transmitting insulin’s signal to the body’s tissues.  The change identified in AKT2 left this signal constantly turned partly on, even during fasting when its absence is essential for liver glucose production.  The study’s results not only offer an explanation to families for this severe metabolic disease, but also suggest an immediate target for new drugs.

Dr Semple said Minic [2009], who is studying for a PhD in Clinical Biochemistry, played an important role in the cellular studies that were reported.

He added: “Marina continues to work closely on the project to understand the finding in more detail, and in particular to inform future novel therapies.”

The prospect of a new pharmaceutical treatment for this rare disorder is dramatically increased due to the fact that the AKT2 molecule is closely related to a molecule that is commonly activated in cancers (AKT1). As a result, the scientists speculate that drugs currently in development (some at the advanced clinical trial stage) that directly block activation of the cancer molecule AKT1 but also happen to block AKT2 could possibly be used to treat this rare form of hypoglycaemia.

Prof Stephen O’Rahilly, co-author of the paper and Co-Director of the Institute of Metabolic Science, said: “I went down to Great Ormond Street to see one of these patients, then a young child, about 10 years ago. It is enormously satisfying that we have finally understood the cause of his problem and very  exciting that a potential therapy immediately suggests itself for this young man and others with this, probably under-recognised, condition.”

Dr Inês Barroso, Joint Head of Human Genetics at the Wellcome Trust Sanger Institute, said: “Beyond the exciting prospect of offering hope for treating diseases such as these, this study is an excellent example of how recent advances in genetic approaches will transform medical diagnostics and treatments.”

Picture credit: Suat Eman and www.freedigitalphotos.net.

Latest News

A leading woman in STEAM

A Gates Cambridge Scholar has been selected as one of the 75 leading women in Science, Technology, Engineering, Arts and Mathematics in India. Yama Dixit will feature in the second edition of the book She Is, published by the Red Dot Foundation in partnership with the Office of the Principal Scientific Adviser, Government of India to mark 75 […]

Tackling the obesity epidemic in Africa

When she left school, Paula-Peace James-Okoro [2022] intended to become a medical doctor, but after starting a degree in Biochemistry she discovered a passion for the subject and for using it to address one of the major health challenges facing Africa – obesity. She says: “In Africa, the rates of metabolic diseases, like obesity and […]

Triple win for Bill Gates Sr. Prize

For the first time three Gates Cambridge Scholars are sharing this year’s Bill Gates Sr. Prize in recognition of their outstanding research and social leadership. Kim van Daalen, Reetika Subramanian and Cynthia Okoye have been selected for the prize which was established by the Gates Cambridge Trustees in June 2012 in recognition of the late […]

Gates Cambridge Annual Report published

The Gates Cambridge Trust’s Annual Report 2021 is now available. It includes a summary of the Trust’s work during the year and the impact of our scholars and alumni in Cambridge and across the world. You can also read about our 20th anniversary celebrations, the many activities of our scholars and alumni, our impact in […]